Key result
In landmark analyses >1 year, stenting for STEMI was associated with a higher rate of very late stent or lesion thrombosis compared to balloon angioplasty (6.1% vs. 2.9%, P=0.002).
Why the study?
Does stenting compared to balloon angioplasty increase the risk of very late stent/lesion thrombosis and target vessel reinfarction in patients with STEMI?
Cohort (n=2,195)
No
Does stenting compared to balloon angioplasty increase the risk of very late stent/lesion thrombosis and target vessel reinfarction in patients with STEMI?
Absolute Event Rate: 6.1% vs 2.9%
p-value: p=0.002
Stenting for STEMI is associated with a higher risk of very late stent/lesion thrombosis and target vessel reinfarction compared to balloon angioplasty beyond 1 year.
OBJECTIVES: This study compares very late outcomes following primary percutaneous coronary intervention for ST-elevation myocardial infarction (STEMI) with stenting versus balloon angioplasty (BA). BACKGROUND: Stenting compared with BA for STEMI improves outcomes at 6-12 months, but comparisons beyond 6-12 months have not been studied. Recent studies have shown that stent thrombosis (ST) continues to increase beyond 3-5 years and may be higher with drug-eluting stents (DES) than bare metal stents (BMS). We hypothesized that there may be a very late hazard with stenting versus BA due to very late ST. METHODS: From 1994 to 2010 consecutive patients with STEMI treated with BA (n = 601) or stenting (n = 1,594) were prospectively enrolled in our registry and followed for 1-16 years. RESULTS: Patients treated with BA were older, were more often female, had more three-vessel disease, and had smaller vessels. Stented patients had trends for less stent/lesion thrombosis (ST/LT) and target vessel (TV) reinfarction at 1 year. In landmark analyses >1 year, stented patients had more very late ST/LT (6.1% vs. 2.9%, P = 0.002) and more TV reinfarction (7.9% vs. 3.1%, P < 0.001) which remained significant after adjusting for baseline risk. The greatest differences in very late outcomes were between DES and BA, but there were also significant differences between BMS and BA. CONCLUSIONS: There appears to be a very late hazard with stenting versus BA for STEMI. These data should encourage new strategies for prevention of very late ST with both BMS and DES including the development of bio-absorbable polymers and stent platforms.
No takes yet. Share an insight, caveat, or question.
Brodie et al. (2013) conducted a cohort in ST-elevation myocardial infarction (STEMI) (n=2,195). Stenting vs. Balloon angioplasty (BA) was evaluated on Very late stent/lesion thrombosis (>1 year) (p=0.002). In landmark analyses >1 year, stenting for STEMI was associated with a higher rate of very late stent or lesion thrombosis compared to balloon angioplasty (6.1% vs. 2.9%, P=0.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: